Our reports
Vaccine: there are questions, but let’s not spoil the mood: a powerful macro and market performance driver
English -
17 Nov 2020
As we said in our editorial released in the wake of the news of Pfizer-BioNTech’s new vaccine six days ago , the announcement is obviously excellent news and we are not going back on that.
Nevertheless, we need to look at the uncertainties liable to shape decision-makers’ and investors’ expectations over the next few months.
Already have an account?
Go to the login page.
Want to create an account?
Go to the registration page.